Until yesterday, shares of CTI BioPharma (CTIC) had been firmly planted in the red in 2020. But sentiment can turn fast in the biotech world and the cancer drug maker provided investors with a dreamy ...

CTI BioPharma (CTIC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.21 per share a year ago. These figures are ...

Acquisition: Sobi acquires CTI BioPharma for ~$1.7 billion, an 85% premium, aligning with Sobi's focus on hematology. Confidence: Main shareholder Investor AB's agreement to rights issue signifies ...

Inrebic was one of two Bristol Myers Squibb's New Products that had the broadest coverage at all patient age levels in January. There have been several changes since then. The most important of which ...

Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is pending. Nasdaq Data provided by Nasdaq ...

A new defensive cyberspace operations facility at Joint Base San Antonio will boost the 35th Intelligence Squadron’s ability to meet growing demands for analysis of intelligence coming from multiple ...

AI that knows how to improve the quality of life beyond the city centers, from those who look to improve cheese production or ...

The Carroll Technology & Innovation Council (CTIC) was conceived in 2001 by the Carroll County Chamber of Commerce as the Carroll Technology Council, to assist businesses and the community with their ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...